NCT00059462View on ClinicalTrials.gov

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
HIV Infections
Interventions
DRUG

Interleukin-2 SA

HAART and Bay 50-4798

DRUG

HAART

HAART alone

Trial Locations (11)

20892

Bethesda

35294

Birmingham

60612

Chicago

90095

Los Angeles

94010

Créteil

94115

San Francisco

95616

Davis

94304-1207

Palo Alto

60611-2908

Chicago

44106-2602

Cleveland

SW10 9NH

London

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY